📋 Ranking Criteria
Tiers are based on: (1) volume and quality of published research, (2) current search momentum, (3) regulatory trajectory in 2026, and (4) research utility — how useful is this compound for studying mechanisms that matter. This is not a safety or efficacy ranking for human use.
S
S-Tier — Exceptional Research Value
Deep publication history, clear mechanism, high search demand, strong 2026 regulatory momentum
BPC-157
Tissue Repair
180+ PubMed publications. Best-studied non-GLP peptide. PCAC vote July 23 makes it the most regulatory-relevant research peptide of 2026. 165K monthly searches.
GHK-Cu
Longevity · Anti-Aging
+1,016% YoY — fastest-growing peptide in search. 30+ year publication history. Multiple well-understood mechanisms: collagen, BDNF, antioxidant, gene expression modulation.
NAD+
Longevity · Cellular Energy
+601% in co-searches with peptide therapy. Central to longevity science. 500+ enzymatic roles. Sirtuin and PARP pathways are among the most-studied in aging research.
GLP-3 RT (Retatrutide)
Metabolic
+512% YoY. 24.2% Phase 2 weight loss. Triple agonist mechanism is genuinely novel. Phase 3 data expected 2026–2027 makes this the most anticipated peptide approval story.
A
A-Tier — Strong Research Value
Well-documented mechanisms, solid search demand, clear applications, some regulatory news
TB-500
Tissue Repair · Systemic
The perfect BPC-157 complement. Systemic cell migration mechanism fills the gap BPC-157 doesn't cover. PCAC July 23 — same momentum as BPC-157. Often searched as a pair.
Semax
Cognitive · Neuroprotection
PCAC July 24 evaluation adds regulatory urgency. Approved in Russia for cerebral ischemia. BDNF upregulation mechanism is one of the most research-validated nootropic pathways.
Selank
Anxiolytic · Cognitive
30 years of Russian research. Human study data (rare for peptides). GABAergic mechanism well-characterized. Removed from Category 2 in April 2026. Low keyword competition.
GLP-2 TRZ (Tirzepatide)
Metabolic
FDA-approved, 1M+ monthly searches. Highest absolute search volume in the catalog. Competitive but the volume justifies content investment. Dual GLP-1/GIP mechanism well-validated.
B
B-Tier — Solid Niche Value
Good research base, growing or steady demand, clear target audience
MT-2 (Melanotan II)
Melanotropic
Steady search demand. Melanocortin receptor research has broad applications beyond tanning — immune modulation, energy balance, sexual function pathways.
MT-1 (Melanotan I)
Melanotropic · Photoprotection
Lower search than MT-2 but photoprotection research angle is increasingly relevant. Naturally occurring analog with longer history than MT-2.
KLOW 80mg Blend
Combination · Convenience
BPC-157 + TB-500 + KPV + GHK-Cu in a single vial. High convenience value for researchers running multi-peptide protocols. Growing demand as the Wolverine Stack concept expands.
C
C-Tier — Worth Watching
Emerging or niche compounds — lower current search but growing trajectory
MOTS-c
Mitochondrial · Longevity
PCAC July 23 evaluation. Mitochondrial peptide category is the "next GHK-Cu" in search trajectory terms. Unusual origin from mitochondrial DNA. Small current volume but expected to accelerate.
Epitalon
Longevity · Telomere
PCAC July 24. Telomere support angle is compelling for longevity researchers. Limited Western literature but decent Russian publication base. Niche audience but dedicated.
✓ All Tier S and A peptides are in stock at Evo Peptides
BPC-157, GHK-Cu, NAD+, GLP-3 RT, TB-500, Semax, Selank, GLP-2 TRZ — plus KLOW 80mg blend and Bacteriostatic Water. Every product third-party tested with COA included.
Frequently Asked Questions
Which research peptide has the most published studies?
Among non-GLP peptides, BPC-157 has the deepest publication record with 180+ PubMed-indexed studies as of 2025, up from 45 in 2020. GHK-Cu has 340+ published studies when including topical applications. NAD+ research spans thousands of papers across multiple disciplines.
Which peptide has the highest search growth in 2026?
GHK-Cu leads at +1,016% YoY, followed by Retatrutide at +512%. NAD+ is up +601% in co-search data with peptide therapy. BPC-157 is up approximately 80% YoY in baseline "peptides" category searches.
What makes a peptide "research-grade"?
Research-grade peptides are synthesized to ≥98% purity by HPLC, verified by mass spectrometry for sequence accuracy, tested for endotoxin levels, and produced in conditions appropriate for laboratory research. A certificate of analysis (COA) from an independent third-party lab is the key documentation requirement.
Research Use Disclaimer — All Evo Peptides products are for research use only and not for human consumption.